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Abstract
Objective: The present study was performed to identify factors associated with a Bacille
Calmette–Gue´rin (BCG) inoculation site change in patients with Kawasaki disease (KD).
Methods: Among patients who had received BCG vaccination and treatment for KD at our
hospital from 2005 through 2016, 177 patients born in 2005 through 2016 were enrolled. The
patients were divided into those with (n¼ 83, change group) and without (n¼ 94, no-change
group) a BCG site change, and the patient demographics, clinical severity, blood examination
results, and echocardiographic findings were compared between the two groups.
Results: The change group was younger at onset and had a shorter interval from vaccination to
onset. A BCG site change was observed in patients who developed the onset of KD symptoms
from 31 to 806 days after BCG vaccination. Multivariate analysis showed that the interval from
vaccination was closely and positively associated with the BCG site change (hazard ratio¼ 0.995,
95% confidence interval¼ 0.993–0.997).
Conclusion: A BCG site change in patients with KD is most closely associated with the interval
from BCG vaccination to onset.
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Introduction
In Japan, Bacille Calmette–Gue´rin (BCG)
vaccination is currently recommended for
infants aged 5 to 8 months. Previously,
when producing the BCG vaccine,1 the pel-
licles were removed from cultured
Mycobacterium bovis BCG Tokyo 172
strain to generate moist bacteria, which
were then triturated and loaded onto
15% (w/v) sodium glutamate solution fol-
lowed by freeze-drying. The freeze-dried
samples were mixed with physiological
saline to make 80-mg/mL suspensions.
Each suspension was applied to the mid-
point of the lateral surface of the upper
arm, and the vaccine was administered
intradermally using a disposable device
with 9 needles according to the multipunc-
ture method (18 needle scars). The BCG
vaccination program in Japan has changed
over time; the current program, in which
the vaccine is given during infancy, has
been implemented since 2005.
Kawasaki disease (KD) is a febrile illness
of unknown etiology affecting more than
10,000 infants per year in Japan. KD is
diagnosed based on six principal symptoms
and supplemental criteria as described in
the Diagnostic Guidelines for Kawasaki
Disease.2 A BCG inoculation site change
is one of the supplemental criteria and is
considered an effective diagnostic criterion
because of its high specificity for KD in
Japan, although its cause and associated
factors remain unidentified.3
Although some studies have shown that
age at onset2 and disease severity4,5 are
major causal factors, none has shown
strong correlations between these factors
and KD. The aim of this study was to iden-
tify factors associated with the development
of a BCG site change in patients with KD
by analyzing clinical findings in patients
who developed KD after BCG vaccination.
Patients and methods
Among patients who had received BCG
vaccination and underwent acute-phase
treatment for KD (including possible/prob-
able cases) after the first onset of symptoms
at our hospital from 2005 through 2016,
those who were born in 2005 through
2016 and started treatment before hospital
day 7 were enrolled in this study. The
patients were divided into those with
(change group) and those without
(no-change group) a BCG site change.
The following factors were compared
between the two groups: (1) demographics,
including the male/female ratio, age at BCG
vaccination, age at onset, and interval from
BCG vaccination to onset; (2) severity of
symptoms, including the presence/absence
and number of principal symptoms and
the number of patients with a confirmed
diagnosis of KD; and (3) severity of abnor-
mal examination results, including blood
examinations [white blood cell, neutrophil,
and platelet counts; hematocrit; and con-
centrations of albumin, aspartate amino-
transferase, alanine aminotransferase,
sodium, total bilirubin, C-reactive protein
(CRP), ferritin, and brain natriuretic pep-
tide] and left ventricular ejection fraction
on echocardiography. The groups were
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also compared for resistance to high-dose
gamma-globulin therapy (2 g/kg per dose)
and the presence or absence of acute-phase
coronary lesions and coronary artery
sequelae.
A BCG site change was defined as local-
ized erythema appearing as a BCG scar
(Figure 1). The severity of abnormal exam-
ination results was determined based on the
worst values obtained before the day of
diagnosis. In addition, to determine the
contribution of host-related factors, rele-
vant factors for nine patients with recurrent
KD symptoms were compared between the
first and second onset of symptoms. Data
on clinical characteristics and severity of
abnormal examination results were com-
pared using Student’s t-test. The principal
symptoms were compared between these
two groups by the v2 test. The significance
level was set at p< 0.05. Statistical analyses
were performed using SPSS 15.0J (SPSS
Japan Inc., Tokyo, Japan).
This study was approved by the
Institutional Ethics Committee (28–40) of
Fukuyama Medical Center, Hiroshima,
Japan and conducted in accordance with
the Declaration of Helsinki. The parents
of each infant provided written informed
consent prior to participation in the study.
Results
Patient demographics
The patient demographics are shown in
Table 1. In total, 177 patients were enrolled
in this study. The change group comprised
83 patients, and the no-change group com-
prised 94 patients. No significant differen-
ces in the male/female ratio or age at BCG
vaccination were observed between the two
groups. Age at onset was significantly lower
in the change group, with the oldest patient
aged 3 years 2 months (p< 0.001). The
interval from vaccination to symptom
onset was significantly shorter in the
change group (p< 0.001). There was a
strong correlation between age at onset
and the interval from vaccination to onset
(r¼ 0.999, p< 0.01).
The distribution of the interval from vac-
cination to onset in both groups is shown
graphically in Figure 2 and tabulated in
Table 2. The shortest and longest intervals
in the change group were 31 and 806 days,
respectively. A total of 100 patients between
both groups experienced symptom onset
during the same period, of whom patients
in the no-change group accounted for 21%
(21 patients). Among the patients with dis-
ease onset in the early period after vaccina-
tion, all 4 patients with symptom onset
within 30 days were in the no-change
group while all 8 patients with onset
between 31 and 60 days were in the
change group. Moreover, all 69 patients
with onset 807 days after vaccination
were in the no-change group.
Figure 1. Change in BCG inoculation site in a
patient with KD: localized erythema in the shape of
the BCG scar (open arrow). BCG, Bacille
Calmette–Gue´rin; KD, Kawasaki disease.
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Severity of symptoms
Table 1 shows the severity of symptoms in
the two groups. Among the principal symp-
toms of KD, cervical lymphadenopathy was
observed in 33% and 71% of the patients in
the change and no-change groups,
respectively, with a significantly lower inci-
dence in the change group (p< 0.001). No
significant differences were observed in the
incidence of any of the other five principal
symptoms. The mean number of principal
symptoms was significantly higher in the
no-change group (5.2 0.8) than in the
change group (4.9 0.8) (p¼ 0.001), but
no significant difference was observed in
the number of patients with a confirmed
diagnosis (78% in the change group and
85% in the no-change group).
Severity of abnormal examination results
Table 3 shows that the change group had
significantly lower neutrophil counts
(p< 0.001) and CRP levels (p< 0.001) and
Table 1. Patient demographics and clinical severity.
Change group No-change group p-value
No. of patients 83 94
Male/female ratio 1.13 0.96 0.59a
Age at BCG vaccination (days) 132 43 122 38 0.11b
Age at onset (years) 1.2 0.6 (0.3–3.2) 3.5 1.9 (0.3–8.8) <0.001b
Days after vaccination 300 216 (31–806) 1185 679 (1–3108) <0.001b
Fever 83 (100) 94 (100)
Bilateral nonexudative conjunctival injection 70 (84) 79 (84) 0.96a
Change in lips and oral cavity 76 (92) 89 (95) 0.41a
Polymorphous exanthema 77 (93) 79 (84) 0.07a
Changes in the extremities 74 (89) 86 (91) 0.60a
Cervical lymphadenopathy 27 (33) 67 (71) <0.001a
No. of principal symptoms 4.9 0.8 5.2 0.8 0.001b
No. of patients with a confirmed diagnosis 65 (78) 81 (85) 0.17a
Values are presented as n, n(%), mean standard deviation, or (minimum–maximum).
av2 test, bStudent’s t-test.
Figure 2. Distribution of interval from vaccination
to onset in the two groups.
Table 2. Interval from vaccination to disease
onset.
Days after
vaccination
Change
group
No-change
group
0–30 0 4
31–60 8 0
61–806 71 21
807 0 69
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significantly higher platelet counts
(p¼ 0.001) and albumin levels (p¼ 0.004).
No significant difference was observed in
the left ventricular ejection fraction at diag-
nosis between the two groups.
The results of a multivariate analysis of
demographic and severity variables are
summarized in Table 4. The interval from
vaccination to symptom onset was identi-
fied as being most closely positively associ-
ated with a BCG site change (hazard ratio,
0.995; p< 0.001; 95% confidence interval,
0.993–0.997). Other factors were not
found to be significant.
Analysis of recurrent cases
As shown in Table 5, 9 of the 177 (5.1%)
patients experienced recurrence of KD
symptoms. The presence or absence of a
BCG site change at recurrence in each
patient is summarized in Table 5. Patients
who experienced recurrence 32, 133, 433,
and 730 days after BCG vaccination had a
BCG site change. Two patients (Nos. 1
and 4) showed different patterns of BCG
site changes between the first and second
onset of symptoms; the change occurred
32 and 730 days after vaccination in patient
Nos. 1 and 4, respectively.
Table 3. Severity of abnormal examination results.
Change group No-change group p-valuea
White blood cells (/lL) 14,300 4600 15,700 6900 0.30
Neutrophils (%) 65.9 10.9 76.3 12.7 <0.001
Hematocrit (%) 33.7 2.9 34.1 2.3 0.36
Platelet count (104/lL) 36.2 9.6 30.9 9.9 0.001
Albumin (g/dL) 3.8 0.4 3.6 0.4 0.004
Aspartate aminotransferase (IU/L) 165 424 155 312 0.88
Alanine aminotransferase (IU/L) 122 243 115 255 0.82
Sodium (mEq/L) 134.9 2.4 134.7 2.5 0.61
Total bilirubin (mg/dL) 1.0 0.9 1.0 0.9 0.71
C-reactive protein (mg/dL) 6.7 4.4 9.8 5.8 <0.001
Ferritin (ng/mL) 158 157 186 117 0.22
Brain natriuretic peptide (pg/mL) 67.0 81.2 76.7 143.0 0.13
Left ventricular ejection fraction (%) 70.9 6.5 70.3 6.3 0.52
Values are presented as mean standard deviation.
aStudent’s t-test
Table 4. Multivariate regression analysis.
Factor HR p-value 95% CI
Age at BCG vaccination 1.004 0.50 0.99–1.02
Days after vaccination 0.995 <0.001 0.993–0.997
No. of principal symptoms 0.57 0.11 0.29–1.14
Neutrophil count 1.04 0.13 0.99–1.08
Platelet count 1.01 0.58 0.97–1.06
Albumin 2.76 0.13 0.73–10.73
C-reactive protein 0.94 0.25 0.84–1.05
Brain natriuretic peptide 0.995 0.07 0.990–1.001
BCG, Bacille Calmette–Gue´rin; CI, confidence interval; HR, hazard ratio.
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Treatment profile and patients’ prognosis
Resistance to high-dose gamma-globulin
therapy (2 g/kg per dose) was observed in
26 of 83 (31%) patients in the change group
and 35 of 94 (37%) patients in the no-
change group; there was no significant dif-
ference between the groups. The incidence
of coronary artery dilatation of at least
þ2.5 SD units (evaluated by the method
reported by Kobayashi et al.6) was 17 of
83 (20%) patients in the change group and
21 of 94 (22%) patients in the no-change
group; residual coronary artery aneurysms
of at least 5 mm were not noted in either
group, and the treatment and prognosis did
not differ between the groups.
Discussion
After BCG vaccination, the patient’s
immunological status changes over time.
BCG vaccination leads to the establish-
ment of anti-infection immunity in about
4 weeks; this is followed by sustained
systemic immune responses over 10 to
15 years, although inoculated BCG bacte-
ria appear to remain at the inoculation
site for only about 6 months.7 A BCG
site change in patients with KD is histo-
logically characterized by marked
infiltration of helper T cells and macro-
phages and expression of interleukin-1b
tumor necrosis factor-a, interferon-c, and
interleukin-2, indicating a delayed hyper-
sensitivity reaction.8,9 Yokota et al.10
investigated various BCG-derived proteins
and found a protein that reacted with only
sera collected during the convalescent stage
of KD. They identified the protein to be
65-kDa heat shock protein (HSP65).
In addition, a mitochondrial protein desig-
nated P1 (human homolog of bacterial
HSP65) also reacted to the convalescent
sera, showing cross-reactive responses to
both mycobacterial HSP65 and P1 antigen
among patients with KD. Furthermore,
Sireci et al.11 showed that a significant
fraction of CD4 and CD8 T-cell clones
from patients with KD recognized the epit-
opes on mycobacterial HSP65 and human
HSP63 (P1 antigen), suggesting a possible
pathogenic role of HSP-specific T cells in
KD. These findings suggest that the cause
of hypersensitivity reactions to BCG in
patients with KD can be attributed to
cross-reactivity between mycobacterial
HSP65 and its human homolog.
Therefore, the most important contributor
to the development of a BCG site change
is whether the condition of the immune
Table 5. BCG inoculation site change in recurrent cases.
Patient
No. Sex
Age at
vaccination
(days)
1st onset 2nd onset
Days at
onset
Days after
vaccination
BCG
change
Days at
onset
Days after
vaccination
BCG
change
1 M 130 137 7  162 32 þ
2 M 97 230 133 þ 530 433 þ
3 F 153 785 632  1080 927 
4 F 127 857 730 þ 1146 1019 
5 M 112 1021 909  1084 972 
6 M 130 1120 990  1832 1702 
7 F 92 1343 1251  1618 1526 
8 M 77 1765 1688  1863 1786 
BCG, Bacille Calmette–Gue´rin; M, male; F, female.
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system allows delayed hypersensitivity
reactions to occur at the site.
In the present study, a BCG site change
was observed in patients who experienced
the onset of KD symptoms from 31 to 806
days after BCG vaccination, but not in
those who experienced onset outside this
interval. There was a clear difference in
the prevalence of a BCG site change
before and after 30 days after vaccination.
This observation can be interpreted as fol-
lows in relation to delayed hypersensitivity:
the anti-infection immunity acquired by
BCG vaccination is associated with the sec-
ondary antigens responsible for the onset of
KD symptoms. During the first 30 days
after BCG vaccination, the BCG-sensitized
T-lymphocyte population has not grown
sufficiently to cause cross-reaction with
KD-related antigens. However, local
immune responses diminish after a long
time has elapsed after BCG vaccination,
such that responses against KD-related
antigens disappear in about 800 days.
A nationwide survey conducted in Japan
from 2005 to 2006 identified a BCG site
change in 49.9% of patients with KD,
with a particularly high prevalence of
70% in children aged 3 to 20 months,
demonstrating an age-related difference in
the prevalence of BCG site change.3 Similar
results have also been reported elsewhere.5
However, some of the infants with KD
symptoms had a BCG site change while
others did not because they had received
BCG vaccination at different ages. These
age-related differences made it difficult to
show a clear difference in the prevalence
of a BCG site change before and after
30 days following vaccination, as observed
in the present study. The histological find-
ings and immunological mechanisms of a
BCG site change also support the appropri-
ateness of considering differences according
to the interval from vaccination instead of
according to age.
Notably, 21% of the patients with symp-
tom onset from 31 to 806 days after BCG
vaccination had no BCG site change. Local
reactions to BCG vaccination are known to
vary among infants depending on immuni-
zation techniques and various other factors.
Such differing patterns of immune acquisi-
tion following vaccination might lead to
varying patterns of cross-reaction with
KD antigens, although this possibility was
not addressed in the present study. In terms
of severity of symptoms, no significant
intergroup difference was observed in the
number of patients with a confirmed diag-
nosis, while the number of principal symp-
toms was significantly lower in the change
group (which had a higher number of youn-
ger patients). This is likely to be attributed
to the known lower prevalence of cervical
lymphadenopathy in younger patients with
KD.12 With respect to the severity of abnor-
mal examination results, the presence of
strong acute inflammation was suggested
in the no-change group. Lai et al.5 reported
increased white blood cell and platelet
counts and increased intensity of inflamma-
tion in patients with a BCG site change,
which is inconsistent with the findings of
the present study. In contrast, a Japanese
nationwide survey of patients with KD per-
formed from 1997 to 1998 showed
decreased neutrophil counts, decreased
CRP levels, and increased platelet counts
in younger patients.13 Therefore, consider-
ing the effect of age, we conducted a multi-
variate analysis including the interval from
vaccination to onset (approximately the age
at onset) and the severity of symptoms and
abnormal examination results, and we
found that a BCG site change was more
closely associated with the interval from
vaccination than with the severity of
inflammation.
KD is common in Japan and other parts
of East Asia, and its prevalence is consid-
ered to reflect the genetic background of the
relevant ethnic groups. The sibling risk
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ratio is 1.5%, and a high percentage
(0.89%) of parents of patients with KD
have a history of KD. Differences in genetic
susceptibility are thus considered to exist
with the same ethnic group. In contrast, a
susceptibility gene for KD has been
reported, and genetic factors are associated
with the onset of KD or the manifestation
of KD symptoms in carriers. Genetic pre-
disposing factors in the host are thought to
be associated with the onset or development
of KD symptoms.14 We therefore investi-
gated whether any changes in these factors
occurred at the first and second onset of
KD symptoms within individual hosts.
Two of the three patients with a BCG site
change (patient Nos. 1 and 4) showed dif-
ferent patterns of development of their
BCG site change at the first and second
onset of KD symptoms depending on the
interval from vaccination; that is, only
symptom onset from 31 to 806 days after
vaccination was associated with a BCG site
change. This was consistent with the rela-
tionship between a BCG site change and the
interval from vaccination to onset. The pre-
sent results suggest that the interval from
vaccination is more pivotal to the develop-
ment of a BCG site change than other fac-
tors, such as host-related factors.
Various potential factors have been iden-
tified as being associated with the develop-
ment of a BCG site change in patients with
KD. Of these factors, the interval from
BCG vaccination to symptom onset was
found to be the most relevant in the present
study. However, this was a single-center ret-
rospective study, and further studies are
needed to verify our results. Analyses of
interleukin-2 and other cytokines were pos-
sible for only a subset of patients in this
study, and the results are accordingly not
included in this report. Although this
study could not determine the exact mech-
anism by which a BCG site change occurs,
these results may contribute to elucidating
the pathogenesis of BCG site changes and
the onset of KD symptoms in future
studies.
Conclusions
A BCG inoculation site change in patients
with KD was more closely associated with
the interval from vaccination to onset than
with the severity of symptoms, abnormal
examination results, or host genetic predis-
posing factors. A BCG site change occurred
only in patients with an onset of KD symp-
toms from approximately 30 to 800 days
after vaccination. During this period,
delayed hypersensitivity reactions between
host anti-infection immunity acquired by
the BCG vaccination and secondary anti-
gens involved in the onset of KD symptoms
might have been induced locally at the site
of the BCG scar.
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